Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

20185,313 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet

Volume 391, Issue 10126, pp. 1163-1173

Field-Weighted Citation Impact: 264.21